Skip to main content
OCULAR THERAPEUTIX, INC logo

OCULAR THERAPEUTIX, INC — Investor Relations & Filings

Ticker · OCUL ISIN · US67576A1007 LEI · 529900ABAWFXOHSIHG03 US Manufacturing
Open in API
Filings indexed 801 across all filing types
Latest filing 2026-02-05 Annual Report
Country US United States of America
Listing US OCUL

About OCULAR THERAPEUTIX, INC

https://www.ocutx.com/

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. The company's primary focus is on transforming the treatment of retinal diseases, such as wet age-related macular degeneration (wet AMD), a leading cause of blindness. Ocular Therapeutix utilizes its proprietary hydrogel-based drug delivery platform, ELUTYX™, to develop sustained-release therapies. This technology is designed to reduce the therapeutic burden on patients by decreasing the frequency of required treatments. The company's lead product candidate, AXPAXLI™ (axitinib intravitreal implant), is in late-stage clinical development for major retinal diseases.

Recent filings

Filing Released Lang Actions
10-K Filing
Annual Report FY 2025
2026-02-05 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC by Ocular Therapeutix, Inc. dated February 5, 2026. It announces the company's financial results for the quarter and year ended December 31, 2025, and includes a press release as Exhibit 99.1. The text explicitly states that the full financial results are in the press release attached as an exhibit, and the 8-K itself is a current report announcing these results. The document is relatively short (3950 characters) and serves as an announcement of financial results rather than the full detailed financial report. According to the classification rules, initial announcements of quarterly or periodical financial results (key highlights only) correspond to an Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2026-02-05 English
S-8 Filing
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Ocular Therapeutix, Inc. It relates to the registration of securities under the Securities Act of 1933 for the 2019 Inducement Stock Incentive Plan. The text includes details about the registration, exhibits, signatures, and legal compliance. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing for securities registration, not a financial report or announcement of voting results, capital changes, or management changes. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is 9393 characters, which is substantial but the content is clearly a registration statement, not a report or announcement of a report publication.
2026-02-05 English
4 Filing
Director's Dealing
2026-02-04 English
4 Filing
Director's Dealing
2026-01-26 English
3 Filing
Director's Dealing
2026-01-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.